DelveInsight
0 FOLLOWERS
We are a business consulting firm with deep industry expertise in life science vertical with core focus on pharma and biotech industries. We consistently help our clients in taking sound decisions facilitating better business performances and achieving incredible growth.
Since its inception, DelveInsight has played a pioneering role in providing state of the art services to its clients and..
DelveInsight
1w ago
DAYVIGO (lemborexant) is an orexin receptor antagonist approved for treating adult patients with insomnia, who ..read more
DelveInsight
1w ago
Ocrelizumab proves superior to first-line therapies in early RRMS, promoting better outcomes. Long-term data spanning ..read more
DelveInsight
1w ago
Inhibikase Therapeutics’ lead product candidate, Risvodetinib (IkT-148009), represents a novel therapeutic approach in the treatment ..read more
DelveInsight
1w ago
DAXXIFY (daxibotulinumtoxinA) injection represents a novel approach to treating cervical dystonia in adults and addressing ..read more
DelveInsight
1w ago
ABBV-951, an innovative investigational drug developed by AbbVie, offers hope for patients with advanced Parkinson's ..read more
DelveInsight
1w ago
LIBERVANT, a diazepam buccal formulation based on PharmFilm technology serves as a beacon of hope ..read more
DelveInsight
3w ago
Brilaroxazine, developed by Reviva Therapeutics, exhibits potent affinity and selectivity against key serotonin and dopamine ..read more
DelveInsight
3w ago
Despite the urgent need for novel treatments, drug development for cognitive impairment associated with schizophrenia ..read more
DelveInsight
3w ago
LYN-005’s once-weekly dosing regimen reduces the pill burden for individuals with schizophrenia and schizoaffective disorders ..read more
DelveInsight
3w ago
In the landscape of schizophrenia treatment, there are significant gaps that affect patients' lives profoundly ..read more